Regeneron Pharmaceuticals Inc. (REGN) and Bayer HealthCare, a subgroup of German conglomerate Bayer AG (BAYRY.PK, BAYZF.PK), have initiated a new Phase 3 trial, named VIVID EAST-DME, to assess the efficacy and safety of EYLEA Injection in the treatment of Diabetic Macular Edema or DME in Russia, China, and other Asian countries. Both the companies are extending their global development program for EYLEA in DME after promising results in the global Phase 2 DME program.
EYLEA was approved in the United States for the treatment of neovascular (wet) Age-related Macular Degeneration (AMD) in November 2011 and for Macular Edema following Central Retinal Vein Occlusion in September 2012.
Bayer HealthCare and Regeneron are collaborating on the global development of EYLEA. Regeneron maintains exclusive rights to EYLEA in the U.S. Bayer HealthCare licensed the exclusive marketing rights outside the United States, where the companies would equally share the profits from any future sales of EYLEA, except for Japan where Regeneron would receive a royalty on net sales.
For comments and feedback: editorial@rttnews.com